Literature DB >> 29873889

Both acute and chronic inflammation are associated with less perineural invasion in men with prostate cancer on repeat biopsy.

Andrew G Kuang1, J Curtis Nickel2, Gerald L Andriole3, Ramiro Castro-Santamaria4, Stephen J Freedland5,6, Daniel M Moreira1.   

Abstract

OBJECTIVES: To evaluate the association between acute and chronic inflammation with the presence of perineural invasion (PNI) in prostate biopsies positive for prostate cancer (PCa).
MATERIAL AND METHODS: We conducted a retrospective analysis of 1 399 prostate biopsies positive for PCa in the Reduction by Dutasteride of PCa Events (REDUCE) study. PCa, acute and chronic prostate inflammation and PNI were assessed by central pathology review. The association between acute and chronic inflammation with PNI was evaluated using chi-squared and Kruskal-Wallis tests, and logistic regression adjusting for clinicopathological and biochemical variables.
RESULTS: The presence of PNI was identified in 133 biopsies (9.5%). In all, 267 biopsies (19.1%) had acute inflammation, 1 038 (74.2%) had chronic inflammation, and 255 (18.2%) had both. The presence of both acute and chronic inflammation had a mutual association (P < 0.001). Chronic inflammation was associated with a lower Gleason score (P = 0.009) and lower tumour volume (P < 0.001), while acute inflammation was associated with lower Gleason score (P = 0.04), lower tumour volume (P = 0.004) and higher prostate-specific antigen levels (P = 0.05). In both univariable and multivariable analyses, chronic prostate inflammation was significantly associated with less PNI (univariable odds ratio [OR] 0.54, 95% confidence interval [CI] 0.37-0.79, P = 0.001; multivariable OR 0.65, 95% CI 0.43-0.99, P = 0.045). Acute prostate inflammation was associated with less PNI only in univariable analysis (univariable OR 0.51, 95% CI 0.29-0.89, P = 0.018; multivariable OR 0.63, 95% CI 0.35-1.13, P = 0.12).
CONCLUSION: Acute and chronic prostate inflammation were both associated with a lower prevalence of PNI in prostate biopsies positive for PCa. If confirmed, this suggests that inflammation and immunomodulation can serve as areas of potential therapeutic design to mitigate PNI in patients with PCa.
© 2018 The Authors BJU International © 2018 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  #ProstateCancer; #pcsm; biopsy; inflammation; perineural invasion; prostatic neoplasm; prostatitis

Mesh:

Substances:

Year:  2018        PMID: 29873889     DOI: 10.1111/bju.14428

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

1.  Simultaneous Treatment with Soluble Forms of GAS1 and PTEN Reduces Invasiveness and Induces Death of Pancreatic Cancer Cells.

Authors:  Lizbeth Daniel-García; Paula Vergara; Araceli Navarrete; Rosa O González; Jose Segovia
Journal:  Onco Targets Ther       Date:  2020-11-17       Impact factor: 4.147

Review 2.  Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome.

Authors:  Simona Mihai; Elena Codrici; Ionela Daniela Popescu; Ana-Maria Enciu; Lucian Albulescu; Laura Georgiana Necula; Cristina Mambet; Gabriela Anton; Cristiana Tanase
Journal:  J Immunol Res       Date:  2018-09-06       Impact factor: 4.818

Review 3.  Current Knowledge of the Potential Links between Inflammation and Prostate Cancer.

Authors:  Tommaso Cai; Raffaella Santi; Irene Tamanini; Ilaria Camilla Galli; Gianpaolo Perletti; Truls E Bjerklund Johansen; Gabriella Nesi
Journal:  Int J Mol Sci       Date:  2019-08-06       Impact factor: 5.923

4.  Preoperative Platelet Count Correlates With Postoperative Perineural Invasion on Specimen in Patients Treated With Radical Prostatectomy.

Authors:  Fangming Wang; Fei Liu; Jing Liang; Feiya Yang; Nianzeng Xing
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

Review 5.  The Role of Perineural Invasion in Prostate Cancer and Its Prognostic Significance.

Authors:  Yuequn Niu; Sarah Förster; Michael Muders
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.